Pharm/Biotech
Resources

Outsourcing Guide

Cont. Education

Software/Reports

Training Courses

Web Seminars

Jobs

Buyer's Guide

Home Page

Pharm Patents /
Licensing

Pharm News

Federal Register

Pharm Stocks

FDA Links

FDA Warning Letters

FDA Doc/cGMP

Pharm/Biotech Events

Consultants

Advertiser Info

Newsletter Subscription

Web Links

Suggestions

Site Map
 

 

 

 

Link:  Pharm/Biotech Resources


Title:  Herbal-based composition for treating acute and chronic myeloid leukemia

United States Patent:  6,967,034

Issued:  November 22, 2005

Inventors:  Bandyopadhyay; Santu (Kolkata, IN); Roy; Keshab Chandra (Kolkata, IN); Ray; Mitali (Kolkata, IN); Banerjee; Goutam (Kolkata, IN); Pal; Bikash Chandra (Kolkata, IN); Biswas; Tanusree (Kolkata, IN); Bhattacharya; Samir (Kolkata, IN)

Assignee:  Council of Scientific and Industrial Research (New Delhi, IN)

Appl. No.:  448398

Filed:  May 30, 2003

Abstract

A new herbal-based composition and method for treatment of CD33+ acute and chronic myeloid leukemia by Piper betel leaf extracts, and to provide a process for the isolation of active fractions from leaves or any other plant parts of Piper betel to treat CD33+ AML and CML with a simplified method of isolation of active components from all plant parts of Piper betel possessing biological activities relevant to the treatment of CD33+ AML and CML.

Description of the Invention

FIELD OF INVENTION

This invention relates to a herbal based composition for treatment of CD33+ acute and chronic myeloid leukemia by Piper betel leaf extracts, fractions of Piper betel leaf extracts and 3-O-p-coumaryl quinic acid purified from Piper betel leaves extract.

BACKGROUND AND PRIOR ART REFERENCES

Mycloid leukemia, both acute (AML) and chronic (CML) are lethal, there is no drug directing towards the destruction of the myeloid cells and these cells poorly respond to chemotherapy, which is always non-specific, thus adversely affecting normal cells. Unique property of the therapy with Piper betel components is the killing of myeloid cancer cells by recognizing CD33+ marker on the cell membrane, leaving normal cells without getting affected.

Myeloid leukemia is usually subdivided into two groups: Acute Myeloid Leukemia (AML) and Chronic Myeloid Leukemia (CML). AML is characterized by an increase in the number of myeloid cells in the bone marrow and an arrest in their maturation. In the United States, the annual incidence of AML is approximately 2.4 per 100,000 and it increases progressively with age, to a peak of 12.6 per 100,000 in adults of 65 years age or older. The CML is a malignant clonal disorder of hematopoietic stem cells. The median age at presentation is 53 years, but it occurs at all age groups, including children. The natural history of CML is progression from a benign chronic phase to a rapidly fatal blast crisis within three to five years or even earlier. The prognosis of CML is also poor inspite of vast advancement of clinical medicine (1). CD33 represents a specific and useful marker in the process of myeloid cell differentiation (2). Recent reports suggest that engagement of CD33 by monoclonal antibody induced apoptosis leading to growth inhibition of proliferation of AML and CML cells in vitro (2,3). Exploiting the myeloid specific expression of CD33, humanized anti-CD33 monoclonal antibody conjugated with anti-cancer drug has been tried in AML patients with significant success (4). With the extract from Piper betel leaves anti-myeloid activity was claimed earlier (Patent filed no. PCT/INOO/00118 dated Dec. 12, 2000).

Hence, applicant's earlier finding is in directed consonance with the present patent filing on Piper betel leaf extract, fractionated leaf extracts and purified compound 3-O-p-coumaryl quinic acid (FIG. 1) obtained from leaf extract for treating CD33+ acute and chronic myeloid leukemia.

Piper betel leaves have a strong pungent aromatic flavour and are widely used in India as a masticatory. Generally, mature or overmature leaves, which have ceased growing but not yet become brittle are used for chewing. The basic preparation for chewing purposes consists of betel leaf smeared with hydrated lime and catechu to which scrapings of arecanut are added; flavourings such as coconut shavings, clove, cardamom, fennel, powdered liquorice, nutmeg and also tobacco are used according to one's taste. In some places prepared Piper betel leaf preparation is covered with silver or gold film. As a masticatory, it is credited with many properties: it is aromatic, digestive, stimulant and carminative. Medicinally it is useful in catarly and pulmonary infections; it is also uses for poultices. The effects of chewing of betel leaves with arecanut and other adjuncts are the excitation of the salivary glands and the irritation of the mucous membrane of the mouth. The red coloration produced is due to a pigment in the arecanut, which manifests itself under the action of alkali in lime and catchu. A mild degree of stimulation is produced, resulting in a sensation of warmth and well-being, besides imparting a pleasant odour. The most important factor determining the aromatic value of the leaf is the amount and particularly the nature of the essential oil present. Betel leaves from different regions vary in smell and taste. The most pungent is the Sanchi type, while the most wild and sweet ones are from Varansai. The betal leaves contain essential oils, the content of oil varies from 0.7 to 2.6 per cent depending upon the varieties of leaves. The oil consists of phenols and terpens. The higher the proportion of phenol the better the quality. An isomer of eugenol named chavibetol (betel phenol; 4-alkyl-2-hydroxy-1methoxy benzene) is considered to be characteristic constituent of betel oil. Betel oil of Indian types contains a predominant phenolic constitutent and used in the treatment of various respiratory problems, either as a local application or by gargle. It has carminative properties. It exhibits in different actions on the central nervous system of mammals. The essential oil and extracts of the leaves possess activity against several Gram-positive and Gram-negative bacteria such as Micrococcus pyogenes var. Albus, Bacillus subtilis and B. Megaterium, Diplococcus pneumoniae, Streptococcus pyogenes, Escherichia coli, Salmonella typhosa, Vibrio comma, Shigella dysenteriae, Proteus vulgaris, Pseudomonas solanacaerum, Sarcina lutea and Erwinia carototora. The essential oil and leaf extracts also showed anti-fungal activity against Asperigillus niger and A. Oryzae, Curvularia lunata and Fusarium oxysporum. The oil is found to be lethal in about 5 miutes to the protozoa, Paramaeceum caudatum (5). Steam-distillate of the leaves showed activity against Mycobacterium tyberculosis.

REFERENCES

  • 1. Sawyers C L, The New England Journal of Medicine, 340 (17), 1330-1340, 1999.
  • 2. Vitale, C; Romagnani, C, et al., Proc. Natl. Acd. Sci. USA, 96 (26), 15091-15096, 1999.
  • 3. Vitale, C et al., Proc. Natl. Acd. Sci, USA, 98 (10), 5764-5769, 2001.
  • 4. Sievers E L, Appelbaum, F R et al., Blood, 93, 3678-3684, 1999.
  •  

    OBJECT OF THE INVENTION

    The main object of the invention is to provide a new herbal-based composition for the treatment of CD33+ acute and chronic myeloid leukemia by Piper betel leaf extracts.

    Another object of the invention is to provide a process for the isolation of active fractions from leaves or any of the plant parts of Piper betel to treat CD33+ AML and CML.

    Still another object of the invention is to provide a simplified method of isolation of active components from all plant parts of Piper betel possessing biological activities relevant to the treatment of CD33+ AML and CML.

    Yet another object of the invention is to provide a new herbal product from active fraction from leaves or any other plant parts of Piper betel for the treatment of CD33+ AML and CML.

    Yet another object of the invention is to provide a herbal compound 3-O-p-coumaryl quinic acid purified from leaves of Piper betel for the treatment of CD33+ AML and CML.

    Yet another object of the invention is to provide a process for the preparation of extract from leaves or any other plant parts of Piper betel for the treatment of CD33+ AML and CML.

    Yet another object of the invention is to provide a simplified method of extract preparation from leaves or any other plant parts of Piper betel for the treatment of CD33+ AML and CML.

    Yet another object of the invention is to provide a process for the preparation of 3-O-p-coumaryl quinic acid from leaves of Piper betel for the treatment of CD33+ AML and CML.

    Yet another object of the invention is to provide a simplified method of preparation of 3-O-p-coumaryl quinic acid from all plant parts of Piper betel for the treatment of CD33+ AML and CML.

    DESCRIPTION OF THE INVENTION

    Accordingly, the present invention provides an herbal-based composition from piper betle leaves for the treatment of CD33+ acute and chronic myeloid leukemia.

    Doses for myeloid leukemia patient depends on the in-vitro efficiency of the drug from piper betel either individually or in combination, the doses of in-vitro application for human myeloid cancer patients may range from 200 mg to 500 mg per day per patient if given as individual fraction (fraction 1 or fraction 9) or as a combination of fraction 1 and fraction 9 in the ratio between 0.1:5 to 5.0.1 preferably in the ratio 1:1 totaling 125 mg to 370 mg per day per patient through intravenous route.

    In an embodiment of the invention relates to evaluation of bioactivity of fractions 1 to 9 isolated from piper betel leaf against cancer cells.

    In an embodiment of the invention relates to evaluation of bioactivity of fractions 1 to 9 isolated from piper betel leaf for the treatment of CD33+ acute and chronic myeloid leukemia.

    The invention also provides a process for isolation of 3-O-p-coumaryl quinic acid from piper betel, which is reported for the first time.

    Another embodiment of the invention relates to a process for the isolation of active fractions from leaves or any other plant parts of Piper betel to treat CD33+ AML and CML.

    Still another embodiment of the invention relates to a simplified method of isolation of active components from all plant parts of Piper betel possessing biological activities relevant to the treatment of CD33+ AML and CML.

    Yet another embodiment of the invention relates to a new herbal composition/fraction from leaves or any other plant parts of Piper betel for the treatment of CD33+ AML and CML.

    Yet another embodiment of the invention relates to new activity of compound 3-O-p-coumaryl quinic acid purified from leaves of Piper betel for the treatment of CD33+ AML and CML.

    Yet another embodiment of the invention relates to a process for the preparation of extract from leaves or any other plant parts of Piper betel for the treatment of CD33+ AML and CML.

    Yet another embodiment of the invention relates to simplified method of extract preparation from leaves or any other plant parts of Piper betel for the treatment of CD33+ AML and CML.

    Yet another embodiment of the invention relates to a process for the preparation of 3-O-p-coumaryl quinic acid from leaves of Piper betel for the treatment of CD33+ AML and CML.

    Yet another embodiment of the invention relates to a simplified method of preparation of 3-O-p-coumaryl quinic acid from all plant parts of Piper betel for the treatment of CD33+ AML and CML.
     

    Claim 1 of 6 Claims

    1. A method of treating either CD33+ acute myeloid leukemia or CD33+ chronic myeloid leukemia by administering a pharmaceutically effective amount of compound 3-O-p-coumaryl quinic acid to a subject in need thereof.

     

    ____________________________________________
    If you want to learn more about this patent, please go directly to the U.S. Patent and Trademark Office Web site to access the full patent.

     

     

    [ Outsourcing Guide ] [ Cont. Education ] [ Software/Reports ] [ Training Courses ]
    [ Web Seminars ] [ Jobs ] [ Consultants ] [ Buyer's Guide ] [ Advertiser Info ]

    [ Home ] [ Pharm Patents / Licensing ] [ Pharm News ] [ Federal Register ]
    [ Pharm Stocks ] [ FDA Links ] [ FDA Warning Letters ] [ FDA Doc/cGMP ]
    [ Pharm/Biotech Events ] [ Newsletter Subscription ] [ Web Links ] [ Suggestions ]
    [ Site Map ]